The protocol studies of Children's Cancer Study Group are designed and carried out by multidisciplinary study committees culled from group membership. Their purpose is twofold. One is to improve the care and survival of children with leukemia, lymphomas and solid tumors. The second is to conduct scientific research, both clinical and laboratory, which will further investigate the epidemiology, prognostic factors, laboratory findings and cytogenetics of childhood cancer. Phase I-II studies involving new agents are done in patients resistant to conventional therapy. Present studies for acute lymphoblastic leukemia are based on grouping patients by prognostic factors into 5 groups, each of which has its own study plan. Separate protocols have been designed for patients who develop testicular or CNS relapse on therapy. High risk leukemia patients receive either a modified LSA2L2 program or a modified BFM (Berlin, Frankfort, Munich) program. Preliminary studies with these programs show an improved survival in high risk and lymphome syndroma patients. Children with acute non-lymphocytic leukemia (ANLL) are to be treated on a 2 arm chemotherapy induction with appropriate patients going to bone marrow transplant after achieving a complete remission, or continuing on a chemotherapy maintenance arm for 5 drug cycles. Induction chemotherapy will use daunomycin and Ara-C or these drugs plus VP16, thioguanine and dexamethasone. Maintenance therapy will use these drugs plus 5-azacytidine, cyclophosphamide, L-asparaginase and vincristine. A new program for stage III-IV Hodgkin's disease will compare the use of MOPP chemotherapy alternating with ABVD vs. ABVD combined with extended field, low dose radiotherapy. Non-Hodgkin's lymphoma is being treated in 3 studies, one for localized disease, one for disseminated lymphoblastic disease and one for non-lymphoblastic disseminated disease. The osteogenic sarcoma study gives preoperative high dose methotrexate and measures anti-tumor effect. Response of the primary tumor dictates the post-op chemotherapy program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Schools of Medicine
Ann Arbor
United States
Zip Code
Neudorf, Steven; Sanders, Jean; Kobrinsky, Nathan et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103:3655-61
Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Casillas, Jacqueline N; Woods, William G; Hunger, Stephen P et al. (2003) Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 25:594-600
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7

Showing the most recent 10 out of 129 publications